Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
None listed
Sponsors
Dr Reddys Laboratories Ltd
Siro Clinpharm Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex, greater than and equal to 18 years of age 2. Patients prescribed eberconazole 1% cream for topical treatment of tinea cruris and tinea corporis by the treating physician. 3. Patients willing to give written informed consent for study participation.
Exclusion criteria
Exclusion criteria: 1. Patients requiring systemic anti-fungal drugs for management of their condition. 2. Pregnant and lactating women. 3. Patients with any significant medical illness that would prevent study participation, at investigatorâ??s discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EFFECTIVENESS EVALUATION Proportion of patients with improvement of signs and symptoms from baseline to 2 weeks of treatment with eberconazole 1% creamTimepoint: Baseline and 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| EFFECTIVENESS EVALUATION 1. Proportion of patients with improvement of signs and symptoms from baseline to 1 week and 3 weeks of treatment with eberconazole 1% cream. 2. Percent change in signs and symptom score from baseline to 1, 2, and 3 weeks of treatment with eberconazole 1% cream. Timepoint: Baseline, 1 week, 2 weeks and 3 weeks;Efficacy EVALUATION 3. Physicianâ??s global assessment of effectiveness and safety at 1st, 2nd and 3rd week of treatment with eberconazole 1% cream. 4. Patientâ??s assessment of effectiveness and acceptability at 1st, 2nd and 3rd weeks of treatment with eberconazole 1% cream. SAFETY EVALUATION 1. Safety will be assessed based on the spontaneous AE reports generated by the patients/clinician and will be reported as per as per marketed product guidelinesTimepoint: Baseline, 1 week, 2 weeks and 3 weeks | — |
Countries
India
Contacts
Public ContactPartha Chatterjee
SIRO Clinpharm pvt Ltd
Outcome results
None listed